Form 8-K - Current report:
SEC Accession No. 0001193125-25-268103
Filing Date
2025-11-06
Accepted
2025-11-06 07:39:43
Documents
13
Period of Report
2025-10-31
Items
Item 2.02: Results of Operations and Financial Condition
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K lnth-20251031.htm   iXBRL 8-K 56774
2 EX-99.1 lnth-ex99_1.htm EX-99.1 814700
3 EX-99.2 lnth-ex99_2.htm EX-99.2 27963
4 GRAPHIC img66337839_0.jpg GRAPHIC 19366
  Complete submission text file 0001193125-25-268103.txt   1080884

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT lnth-20251031.xsd EX-101.SCH 26007
15 EXTRACTED XBRL INSTANCE DOCUMENT lnth-20251031_htm.xml XML 4941
Mailing Address 331 TREBLE COVE ROAD NORTH BILLERICA MA 01862
Business Address 331 TREBLE COVE ROAD NORTH BILLERICA MA 01862 978 671-8001
Lantheus Holdings, Inc. (Filer) CIK: 0001521036 (see all company filings)

EIN.: 352318913 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36569 | Film No.: 251456201
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)